CONCLUSIONS
In this preplanned analysis of Chinese patients enrolled in CheckMate 649, nivolumab plus chemotherapy resulted in clinically meaningful improvements in OS, PFS, ORR and DOR compared with chemotherapy alone, and the safety profile was acceptable and showed no new safety signals, consistent with results from the global study population.